PRODUCT INFORMATION



Tosufloxacin (tosylate)

Item No. 21427

CAS Registry No.: 115964-29-9

Formal Name: 7-(3-amino-1-pyrrolidinyl)-1-(2,4-

> difluorophenyl)-6-fluoro-1,4-dihydro-4oxo-1,8-naphthyridine-3-carboxylic acid

4-methylbenzenesulfonate


MF: $C_{19}H_{15}F_3N_4O_3 \bullet C_7H_8O_3S$

FW: 576.5 **Purity:**

UV/Vis.: λ_{max} : 221, 269, 341 nm Supplied as: A crystalline solid

-20°C Storage: Stability: ≥4 years

Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.



Laboratory Procedures

Tosufloxacin (tosylate) is supplied as a crystalline solid. A stock solution may be made by dissolving the tosufloxacin (tosylate) in the solvent of choice, which should be purged with an inert gas. Tosufloxacin (tosylate) is soluble in organic solvents such as DMSO and dimethyl formamide. The solubility of tosufloxacin (tosylate) in these solvents is approximately 30 mg/ml. Tosufloxacin (tosylate) is slightly soluble in ethanol.

Tosufloxacin (tosylate) is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, tosufloxacin (tosylate) should first be dissolved in DMSO and then diluted with the aqueous buffer of choice. Tosufloxacin (tosylate) has a solubility of approximately 0.33 mg/ml in a 1:2 solution of DMSO:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day.

Description

Tosufloxacin is a fluoroquinolone antibiotic. It has activity against diverse aerobic and anaerobic bacteria in vitro. Tosufloxacin is also effective against bacterial persisters, showing significant activity against S. aureus and uropathogenic E. coli persisters.^{3,4} As with many other quinolones, tosufloxacin use can be associated with significant side effects.5

References

- 1. Espinoza, A.M., Chin, N.-X., Novelli, A., et al. Comparative in vitro activity of a new fluorinated 4-quinolone, T-3262 (A-60969). Antimicrob. Agents Chemother. 32(5), 663-670 (1988).
- 2. Fernandes, P.B., Chu, D.T.W., Swanson, R.N., et al. A-61827 (A-60969), a new fluoronaphthyridine with activity against both aerobic and anaerobic bacteria. Antimicrob. Agents Chemother. 32(1), 27-32, (1988).
- Niu, H.Y., Cui, P., Yee, R., et al. A clinical drug library screen identifies tosufloxacin as being highly active against Staphylococcus aureus persisters. Antibiotics (Basel) 4(3), 329-336 (2015).
- Niu, H.Y., Cui, P., Shi, W., et al. Identification of Anti-Persister Activity against Uropathogenic Escherichia coli from a Clinical Drug Library. Antibiotics (Basel) 4(2), 179-187 (2015).
- 5. Rubinstein, E. History of quinolones and their side effects. Chemotherapy 47(Suppl. 3), 44-48 (2001).

WARNING
THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

uyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website

Copyright Cayman Chemical Company, 12/05/2022

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD ANN ARBOR, MI 48108 · USA PHONE: [800] 364-9897

[734] 971-3335

FAX: [734] 971-3640 CUSTSERV@CAYMANCHEM.COM WWW.**CAYMANCHEM**.COM